• Text size
  • Normal
  • Big

Company History

April 2017: Ophthalmic viscoelastic preparation business containing BBG250 was transferred to D. Western Therapeutics Institute, Inc.
February 2017: A business and capital alliance agreement signed with Nikon Corporation in the field of regenerative medicine.
April 2016: A collaborative research agreement signed with Universal Cells, Inc. regarding application of their genome editing technology to process iPS cells.
January 2016: A license agreement signed with Athersys, Inc. for the development and commercialization of novel cell therapy treatments, including MultiStem® for the treatment of ischemic stroke in Japan.
October 2015: Opening of Yokohama laboratory  in Yokohama City University Advanced Medical Research Center
June 2015: Listed on the Tokyo Stock Exchange market Mothers (code: 4593).
October 2014: Start of collaborative research with Yokohama City University on cellular and tissue-based products using iPS and other cells.
September 2014: Main office was moved to Minato-ku, Tokyo.
February 2014: Sighregen Co.,Ltd.., a joint venture company with Sumitomo Dainippon Pharma Co., Ltd., was established.
December 2013: Agreement signed with Sumitomo Dainippon Pharma Co., Ltd. on the joint development in Japan of iPS cell–derived RPE cells for the treatment of age-related macular degeneration. A patent licensing agreement and a joint venture contract was also signed.
Ophthalmic viscoelastic preparation business was transferred from Aqumen Biopharmaceuticals K.K.
October 2013: Opening of our laboratory (currently the Kobe Research Institute) in Chuo-ku, Kobe.
September 2013: Business name was changed to HEALIOS K.K.
The Tokyo office and the main office were moved to Chuo-ku, Tokyo.
March 2013: A patent licensing agreement was concluded with RIKEN, on RPE cells for the treatment of age-related macular degeneration.
February 2013: A patent licensing agreement was concluded with iPS Academia Japan, Inc. on iPS cell basic technology related to cellular therapy products containing RPE cells as an active ingredient.
December 2012: Tokyo office was opened in Chiyoda-ku, Tokyo.
August 2011: Healios joins the Riken Venture system.
February 2011: Retina Institute Japan, K.K. (currently HEALIOS K.K.) was established in Higashi-ku, Fukuoka City.
Discussions were initiated on strategies to commercialize RPE cell transplantation as a treatment for age-related macular degeneration.